BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)		1 Months Ended	12 Months Ended
	Jul. 17, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Current operating activities			$ 2,500,000
Sale of common stock			7,250,000
Current operating activities			(1,684,039)	$ (1,293,023)
Cash on hand			$ 2,212,548
Economic life of the patent			10 years
Revenue relates to certification			$ 4,995
Research and development costs			324,629	$ 732,698
Brachytherapy Product Line [Member]
Property, Plant and Equipment [Line Items]
Current operating activities			$ 5,000,000
Offering term			Over the next 12 to 48 months, the Company believes it will cost approximately $9 million to: (1) fund the FDA approval process to conduct human clinical trials; (2) conduct Phase I, pilot, and clinical trials; (3) activate several regional clinics to administer IsoPet® across the county; (4) create an independent production center within the current production site to create a template for future international manufacturing; and (5) initiate regulatory approval processes outside of the United States. The proceeds to be raised from the Regulation A+ Offerings will be used to continue to fund this development.
Radionuclide Therapy Product Line [Member]
Property, Plant and Equipment [Line Items]
Current operating activities			$ 2,500,000
Offering term			Over the next 36 months, the Company believes it will cost approximately $8.0 to $9.0 million to: (1) fund the FDA approval process to conduct human clinical trials; (2) conduct Phase I, pilot, clinical trials; (3) activate several regional clinics to administer IsoPet® across the U.S.; (4) create an independent production center within the current production site to create a template for future international manufacturing; and (5) initiate regulatory approval processes outside of the United States.
Warrant [Member]
Property, Plant and Equipment [Line Items]
Number of common stock shares issued, shares		4,998,000
Number of warrants issued		18,797,000		18,797,000
Common Stock [Member]
Property, Plant and Equipment [Line Items]
Number of common stock shares issued, value			$ 2,266,000
Number of common stock shares issued, shares		2,499,000	24,950,000
Common Stock [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Number of common stock shares issued, value	$ 60,000,000
Private Placement [Member]
Property, Plant and Equipment [Line Items]
Number of common stock shares issued, value				$ 1,179,245
Number of common stock shares issued, shares				16,132,000

VIVOS INC 10-K